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INTRODUCTION
Peroxisome proliferator-activated receptor (PPAR)γ is a
nuclear hormone receptor that, with the retinoid X recep-
tor (RXR), binds as a heterodimer to the PPAR response
element (PPRE), a direct repeat of ‘AGGTCA’ gapped by a
nucleotide. PPAR is trans-activated by several agonists,
including 15-deoxy-∆
12,14-prostaglandin J2 (15dPGJ2) and
thiazolidinediones (TZDs); the latter are widely used as
insulin-sensitizers in the treatment of diabetes [1] (Fig. 1).
Recently, pleiotropic effects of PPARγ agonists in the vas-
culature have been demonstrated. These effects are inde-
pendent of blood glucose-lowering activity and include
protection against the progression of hypertension, ather-
osclerosis, and renal dysfunction [2]. In this review, we
REVIEW
The nuclear hormone receptor PPARγ is activated by several agonists, including members of the thiazolidine-
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and Ang-II-induced adrenal aldosterone synthesis/secretion. PPARγ agonists also inhibit the progression of ath-
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thromboxane A2 system, as well as the protection of endothelial function. Moreover, PPARγ-agonist-mediated
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animal models of the disease, and in non-diabetic renal dysfunction. The renal protective activities may reflect, at
least in part, the ability of PPARγ agonists to lower blood pressure, protect endothelial function, and cause
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Figure 1. Schematic representation of PPARγ/RXR het-
erodimer binding to the PPRE on DNA. PPAR, peroxisome pro-
liferator-activated receptor; RXR, retinoid X receptor; PPRE,
PPAR response element. Modified figure from Sugawara et al.
Endocr J 2010;57:847-852 with permission from The Japan
Endocrine Society [3]. 20 The Korean Journal of Internal Medicine Vol. 26, No. 1, March 2011
discuss recent findings regarding the additional beneficial
aspects of PPARγ agonists in the vasculature, including
conclusions based on our own data.
Effects of PPARg agonists in hypertension
The blood-pressure-lowering effect of TZDs was recent-
ly demonstrated in a clinical study [4] and in the PROactive
(PROspective pioglitAzone Clinical Trial In macroVascular
Events) study, in which 5,238 type 2 diabetic patients
were enrolled. Among the results of that trial, treatment
with the TZD pioglitazone was shown to significantly
decrease (3 mmHg) systolic blood pressure [5]. Because
the renin-angiotensin (Ang)-aldosterone system (RAAS)
plays the most important role in the progression of hyper-
tension, we examined the effects of several PPARγ ago-
nists on Ang II type 1 receptor (AT1R) expression in vascu-
lar smooth muscle cells (VSMCs). Interestingly, 15dPGJ2,
as well as TZDs (pioglitazone,  troglitazone, rosiglitazone),
dose-dependently decreased the expression of AT1R
mRNA [6,7].
Transcriptional analysis using the rat AT1R gene pro-
moter (-1969/+104) and AT1R mRNA stability analysis
using actinomycin D together revealed that PPARγ ago-
nists decrease AT1R expression at the transcriptional
level. Mutation analysis of the promoter demonstrated
that transcriptional suppression was mediated within the -
58/-34 region (TGC AGA GCA GCG ACG CCC CCT AGG
C) of the AT1R gene promoter, which contains a GC-box-
related sequence (underlined), but lacks a PPRE [6] (Fig.
2). Instead, the transcription factor Sp1 was shown to bind
to and trans-activate the promoter region [6]. Over-
expression of PPARγ and Sp1, followed by transcriptional
analysis, electrophoretic mobility shift assay, and glu-
tathione S-transferase pull-down assay, revealed that ago-
nist-activated PPARγ does not bind to the -58/-34 region,
but rather to Sp1 via a protein-protein interaction [6].
Moreover, Sp1 binding to the region was inhibited by co-
incubation with PPARγ [6]. These results suggested that
PPARγ-agonist-induced transcriptional suppression of the
AT1R gene is mediated by the inhibition of Sp1 binding to
the -58/-34 region through a protein-protein interaction
between agonist-activated PPARγ and Sp1 (Fig. 2).
Furthermore, transcriptional suppression was abrogated
by the over-expression of co-activator CERB-binding pro-
tein (CBP) and PPARγ phosphorylation by mitogen-acti-
vated protein (MAP) kinase [8], most likely due to the
functional modification of PPARγ (Fig. 2). PPARγ-agonist-
mediated suppression of AT1R expression was also
demonstrated in Ang-II-infused rats [9,10]. Moreover,
PPARγ agonists have been shown to suppress Ang-II-
induced phosphatidylinositol 3-kinase and MAP kinase
Figure 2. Possible mechanism of PPARγ-agonist-mediated
transcriptional suppression of the AT1R gene promoter.
Agonist-activated PPARγ may inhibit Sp1 binding to the GC-
box-related sequence through a protein-protein interaction,
which, in turn, would result in transcriptional suppression. The
co-activator CBP and the phosphorylation of PPARγ by MAP
kinase may together modulate PPARγ function. PPAR, peroxi-
some proliferator-activated receptor; AT1R, Ang II type 1 recep-
tor; CBP, CERB-binding protein. Modified figure from
Sugawara et al. Endocr J 2010;57:847-852 with permission
from The Japan Endocrine Society [3].
a
Figure 3. Possible effects of PPARγ agonists against atheroscle-
rosis and hypertension through suppression of RAAS and the
thromboxane system. PPAR, peroxisome proliferator-activated
receptor; RAAS, renin-angiotensin (Ang)-aldosterone system;
TX, thromboxane; TXS, TX synthase; TXR, TX receptor, VSMC:
vascular smooth muscle cells. Modified figure from Sugawara et
al. Endocr J 2010;57:847-852 with permission from The Japan
Endocrine Society [3]. Sugawara A, et al. Effect of PPARγ agonist 21
[10] and to ameliorate Ang-II-mediated inflammatory
responses by interfering with the Toll-like-receptor-4-
dependent signaling pathway [11]. Additionally, using
human adrenal H295R cells, we recently found an
inhibitory effect of PPARγ agonists on Ang-II-induced
aldosterone synthase expression and aldosterone secre-
tion [12]. Thus, PPARγ agonists not only down-regulate
AT1R expression but also inhibit Ang-II-mediated signal-
ing pathways and adrenal aldosterone synthesis/secre-
tion, which, together, may result in RAAS suppression
(Fig. 3). The ability of PPARγagonists to lower blood pres-
sure has been reported in Ang-II-infused Sprague-Dawley
rats [9,10], spontaneously hypertensive rats [13], deoxy-
corticosterone acetate-salt rats [14], and hypertensive
double-transgenic mice expressing human renin and
human angiotensinogen transgenes [15]. Conversely,
transgenic mice expressing a dominant-negative PPARγ
P465L mutation exhibited hypertension [16], consistent
with the phenotype of patients with an equivalent PPARγ
P467L mutation [17], without affecting RAAS compo-
nents. Moreover, genetic manipulation of mice with vary-
ing PPARγ expression demonstrated that blood pressure
was lowered by an increase in receptor expression and
increased when levels of the receptor were reduced [18].
Taken together, these results suggest that the decrease in
blood pressure mediated by PPARγ agonists occurs
through several different mechanisms in addition to
RAAS inhibition.
Effects of PPARγ agonists in protection against
atherosclerosis
Thromboxane (TX) A2, which is generated from
prostaglandin H2, stimulates the contraction and prolifer-
ation of VSMCs and may be involved in the progression of
atherosclerosis. We thus examined the effect of PPARγ
agonists on the expression of TX synthase (TXS) in
macrophages [19] and the TX receptor (TXR) in VSMCs
[7,20]. PPARγ agonist suppressed both TXS and TXR
expression at the transcriptional level [7,19,20]. Detailed
analysis revealed that agonist-activated PPARγ inhibited
nuclear factor E2-related factor 2 (NRF2) binding to DNA
of the TXS gene [19], and Sp1 binding to DNA of the TXR
gene [20], in both cases via protein-protein interactions.
Accordingly, PPARγ agonists may suppress the progres-
sion of atherosclerosis through inhibition of both the TX
system, including the synthesis and action/signal-trans-
duction function of TXA2(Fig. 3), and RAAS.
Atherosclerosis is usually preceded by endothelial dys-
function, whereas PPARγ agonists have been reported to
improve the function of these cells not only in streptozo-
tocin-induced diabetic rats [21] and diabetic db/db mice
[22], but also in type 2 diabetic patients [23] and non-dia-
betic patients with coronary artery disease [24]. Additionally,
transgenic mice specifically expressing dominant-negative
PPARγ in endothelium developed endothelial dysfunction
in response to a high-fat diet [25]. PPARγ agonists have
also been reported to reduce carotid intimal-medial thick-
ness (CIMT) and in-stent restenosis after coronary inter-
vention in diabetic and non-diabetic patients [26], neoin-
tima formation after balloon injury in rats [27], and in-
stent restenosis in atherosclerotic rabbits [28]. Meta-
analysis of controlled trials involving type 2 diabetic
patients found a significant reduction in CIMT and pulse
wave velocity by PPARγ agonists of the TZD group [29].
We examined the direct effect of PPARγ agonists on
endothelial gene expression by performing DNA microar-
ray analyses. In those experiments, confluent human
umbilical vein endothelial cells (HUVEC) were treated for
24 hours with the TZD pioglitazone, at a concentration
(100 nM) mimicking the serum concentration in patients
after a single oral administration. RNA extracted from the
cells was processed for DNA microarray analyses using
Human Genome Oligo Set (Operon Biotechnologies Inc.,
Huntsville, AL, USA), allowing the analysis of approxi-
mately 35,000 genes. Representative regulated genes are
shown in Table 1. Among the genes induced by pioglita-
zone were tissue inhibitor of metalloproteinases-3, prosta-
cyclin receptor, kallikrein 6 and 11, prostaglandin E2
Table 1. Effects of PPARγagonist pioglitazone on endothe-
lial gene expression
Genes up-regulated by pioglitazone treatment
Tissue inhibitor of metalloproteinases-3 3.0-fold 
Prostacyclin receptor 5.8-fold
Kallikrein 6 2.6-fold
Kallikrein 11 5.6-fold
Prostaglandin E2 receptor, EP1 subtype 3.7-fold
Microsomal glutathione S-transferase 3 2.1-fold
Genes down-regulated by pioglitazone treatment 
Matrix metalloproteinase-10 0.45-fold 
Plasminogen activator inhibitor-2 0.49-fold
PPAR, peroxisome proliferator-activated receptor. Modified fig-
ure from Sugawara et al. Endocr J 2010;57:847-852 with per-
mission from The Japan Endocrine Society [3]. receptor (EP1 subtype), and microsomal glutathione S-
transferase 3. Suppressed genes included matrix metallo-
proteinase-10 and plasminogen activator inhibitor-2 [30].
The protection of endothelial function by PPARγ agonists
may thus proceed through the regulation of gene expres-
sion. Recently, PPARγ agonists were reported to stimulate
endothelial nitric oxide (NO) production in HUVECs [31]
and to increase the number and function of endothelial
progenitor cells in patients with coronary artery disease
[32]. Additionally, disruption of the endothelium-specific
PPARγ in mice resulted in the reduction of vascular NO
production without affecting endothelial NO synthase
expression [33]. These observations, in addition to our
DNA microarray findings, may also explain the anti-
atherogenic effects of PPARγagonists.
Effects of PPARβ agonists in renal dysfunction
To examine the intra-renal localization of PPARγ pro-
tein, we generated an isoform-specific anti-PPARγ anti-
body, which was then used in the immunohistochemical
analysis of Sprague-Dawley rat kidneys [34,35]. PPARγ
protein was observed to be widely expressed in the nuclei
of mesangial and epithelial cells in the glomeruli, proximal
and distal tubules, loop of Henle, and medullary collecting
ducts [34]. Additionally, the protein was detected in the
intima/media of the renal vasculature [34]. We previously
reported the vasodilating effects of the TZD troglitazone
on the glomerular efferent arterioles of microdissected
rabbit kidneys [36]. As suggested by the immunohisto-
chemical data, these vasodilating effects may be mediated
by PPARγ expressed in the intra-renal arterioles. The
expression of PPARγ protein was also induced in distal
tubules and cortical collecting ducts following administra-
tion of the TZD rosiglitazone to Sprague-Dawley rats [35].
These findings are potentially relevant in terms of patho-
physiology, because TZDs have been reported to expand
body fluid volume by the PPARγ-mediated stimulation of
renal salt absorption through epithelial Na
+channels [37].
Renal protective effects of PPARγ ligands on type 2 dia-
betic patients with nephropathy, especially with respect to
a reduction in urinary albumin, have recently been report-
ed [38]. A meta-analysis of 15 studies involving 2,860 dia-
betic patients demonstrated a significant decrease in uri-
nary albumin excretion in response to TZD-type PPARγ
agonists [39]. Additionally, similar effects were observed
in animal experiments using various rodent models of
type 2 diabetes [38]. The mechanisms by which PPARγ
agonists reduce urinary albumin remain unclear. However,
together with their vasodilating effect on glomerular effer-
ent arterioles [36], a lowering of blood pressure and an
improvement of endothelial dysfunction may be cumula-
tively involved. Additionally, a recent study described the
renal protective effect of PPARγ agonists against non-dia-
betic renal disease [40], indicating their general useful-
ness in the treatment of chronic kidney disease. We have
also demonstrated a renal protective effect of the TZD
rosiglitazone against cyclosporine-induced renal injury in
Sprague-Dawley rats [41]. Moreover, the renal protective
effect of the TZD pioglitazone against aging-related renal
injury has been reported [42].
CONCLUSION
More than a decade has passed since the pleiotropic
effects of PPARγ agonists were first reported. However,
novel effects of PPARγagonists are still being described on
almost a monthly basis. In addition to the effects of these
agents discussed in this review, anti-cancer activities of
PPARγ agonist were recently reported [43]. We have also
reported inhibitory effects of TZD-type PPARγ agonists on
cell growth and REG (regenerating gene) Iα expression in
gastrointestinal cancer cell lines [44]. It thus seems likely
that the usefulness and effectiveness of PPARγ agonists
against lifestyle-related diseases will be increasingly
appreciated. This, in turn, may lead to further approved
clinical applications of PPARγ agonists in the treatment of
hypertension, atherosclerosis, and renal dysfunction, in
addition to diabetes.
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